GlycoMimetics, Inc. (GLYC)
NASDAQ: GLYC · Real-Time Price · USD
0.2028
-0.0072 (-3.43%)
Apr 1, 2025, 10:21 AM EDT - Market open
Company Description
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
GlycoMimetics, Inc.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 10, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Harout Semerjian |
Contact Details
Address: P.O. Box 65 Monrovia, Maryland 21770 United States | |
| Phone | 240 243 1201 |
| Website | glycomimetics.com |
Stock Details
| Ticker Symbol | GLYC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001253689 |
| CUSIP Number | 38000Q102 |
| ISIN Number | US38000Q1022 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Harout Semerjian | Chief Executive Officer and President |
| Brian M. Hahn | Senior Vice President and Chief Financial Officer |
| Stephanie R. Irish CPA | Vice President of Accounting |
| Christian B. Dinneen-Long | General Counsel and Company Secretary |
| Bruce Johnson | Senior Vice President and Chief Commercial Officer |
| Chinmaya Rath | Senior Vice President and Chief Business Officer |
| Shantha Tyavanagimatt Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 28, 2025 | 425 | Filing |
| Feb 27, 2025 | 425 | Filing |
| Feb 25, 2025 | 425 | Filing |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 18, 2025 | S-4 | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | 425 | Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 13, 2025 | 10-K | Annual Report |
| Jan 31, 2025 | 8-K | Current Report |